Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology firm, will participate in the Canaccord Genuity 41st Annual Growth Conference from August 10-12, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology firm, will participate in the Canaccord Genuity 41st Annual Growth Conference from August 10-12, 2021. CEO Brian Sullivan will engage in a virtual fireside chat on August 12, 2021, at 8:30 a.m. ET. Interested parties can access the live webcast here or via the company’s Investors page. Celcuity focuses on enhancing cancer patient outcomes through its CELsignia diagnostic platform and related therapeutic strategies.
Details
News Market Reaction – CELC
The recorded move for CELC in the trading session of this news was +4.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, MN / ACCESSWIRE / August 5, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled to present in a virtual fireside chat at 8:30 a.m. ET on Thursday, August 12, 2021.
A live webcast of the fireside chat will be available at: https://wsw.com/webcast/canaccord60/celc/2404732. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://celcuity.com/investors/events-webcasts/ with a replay available shortly after the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic and therapeutic strategy. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Its therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
763-392-0123
Westwicke ICR
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886
SOURCE: Celcuity Inc.
View source version on accesswire.com:
https://www.accesswire.com/658530/Celcuity-to-Participate-in-the-Canaccord-Genuity-41st-Annual-Growth-Conference
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.